<DOC>
	<DOCNO>NCT00367913</DOCNO>
	<brief_summary>To date key drug treatment MAIS , M.malmoense M.xenopi ( Opportunist Mycobacteria rifampicin ethambutol . Clarithromycin Ciprofloxacin active vitro specie mycobacteria . The primary aim study compare agent supplement rifampicin ethambutol . A secondary aim ass vale immunotherapy M.vaccae .</brief_summary>
	<brief_title>Clarithromycin v Ciprofloxacin Added Rifampicin + Ethambutol , Opportunist Mycobacterial Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Ethambutol</mesh_term>
	<criteria>Patients pulmonary disease due M.avium intracellulare , M.malmoense M.xenopi . Aged 16 . With clinical and/or radiological evidence active infection produce sputum positive culture least 2 occasion . Pregnant woman woman childbearing age take adequate contraceptive precaution . Patients sputum currently positive culture M.tuberculosis M.bovis . Patients AIDS know HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>pulmonary disease</keyword>
	<keyword>Treatment Opportunist Mycobacteria</keyword>
	<keyword>Clarithromycin</keyword>
	<keyword>Ciprofloxacin</keyword>
	<keyword>M.vaccae</keyword>
	<keyword>Pulmonary disease cause Opportunist Mycobacteria</keyword>
</DOC>